The NET Alliance™ and Novartis Oncology continue their commitment to improving knowledge and management of neuroendocrine tumors, and empowering patients to be more informed advocates.

  • А
  • А
  • А

Download More Information About Specific Types of NET: 

Evidence of an increasingly common problem

A 2.7-fold increase in incidence

According to Surveillance, Epidemiology, and End Results (SEER) data, the age-adjusted incidence of NET rose from 1.9 to 5.25 cases per 100,000 people between 1973 and 2004.4 These are the most current SEER data available encompassing all NET types and anatomic locations.

The diagnosed incidence of NET is predicted to continue rising at a faster rate than other malignant neoplasms.7 This may be due to improved surveillance and diagnostic techniques, and may also be attributed, in part, to the increased use of gastrointestinal (GI) imaging modalities, such as gastroscopy, colonoscopy, and capsule endoscopy, in routine clinical practice.8,9

Incidence increased faster than that of other neoplasms (SEER data, 1973-2004)

Have you seen NET in your practice?

SEER data (1973-2004) also demonstrate that the prevalence of NET is similar to that of other types of GI cancers.4

Most NET occur sporadically. However, some may be associated with genetic syndromes, notably multiple endocrine neoplasia type 1 (MEN-1), as well as MEN-2a and MEN-2b.2,3

Chart showing that neuroendocrine tumors (NET) are more prevalent than stomach and pancreatic cancers combined.

Early NET detection may help reduce rates of metastatic disease

As with other solid tumors, 5-year survival rates for patients with NET depend largely on the tumor histology and extent of disease. The table at right shows 5-year and median survival for both well-differentiated NET and poorly differentiated neuroendocrine neoplasms, according to long-term SEER data (1973-2004).4

5-year survival rates for patients with neuroendocrine tumors (NET)

About 50% of patients with reported disease stage have either regional or distant metastases at diagnosis.4

This reflects, in part, the long delay that can occur (up to 5 to 7 years for certain types of NET)2 before patients are definitively diagnosed and optimally managed.

The extent of disease at diagnosis also varies according to location of the primary tumor, as shown at right.4

Note that survival rates can vary across studies. Institutional series tend to report longer survival times than population-based studies, such as SEER.4

<p>The extent of disease at diagnosis also varies according to location of the primary tumor, as shown at right.<sup>4</sup></p>

Download More Information About Specific Types of NET: 

Resource for Nurses: Take the NET Nurse Quiz! 

The NET Nurse Quiz is an interactive quiz to test your knowledge on neuroendocrine tumors and how the disease affects your patients.

Are you ready for the quiz?